To the Editor,
Recently in this journal, Nijns et al. 1 provided convincing data that polytetrafluoroethylene (PTFE) devices loaded with stem cell-derived pancreatic endodermal (hu-iPSC-PE) cells implanted in the subcutaneous (SC) tissue of athymic, immune-compromised (nude) rats engendered dense fibrotic capsule formation resulting in virtually no functional beta cells. This observation was remarkable in two aspects. First, their observations in the nude rat were in stark contrast to their earlier reports that the same type of implant (device and cells) did not provoke an FBR in both the athymic nude mouse 2 using human islets and in the severe combined immunodeficiency (SCID)/beige mouse3,4 with hu-iPSC-PE cells; instead the cells had proven capable of establishing a functional beta cell mass (FBM). Because similar devices and cells have led to fibrotic reactions in man 5 , they concluded that observations from the nude rat model are more clinically relevant than findings in either the nude or SCID mouse 1 . Second, and more broadly, they have demonstrated that the athymic nude rat is indisputably capable of mounting a foreign body response (FBR) to implanted devices containing cells. In the past, this assumption has often been challenged despite the knowledge that nude rats, while being T-cell deficient 6 , have normal B-cell populations. The FBR does not require T-cells7–9.
Here we write in support of the Pipeleers group’s conclusion regarding the use of the nude rat model for preclinical investigations of biocompatibility of encapsulated cells 1 . Furthermore, we extend their observations to biomaterials and devices devoid of cellular contents. As part of a more expansive study of membranes potentially useful for cell encapsulation, we implanted PTFE membranes in the dorsal SC tissues of male Crl:NIH-Foxn1 rnu athymic nude rats. The membranes or devices did not contain cells of any kind. After 3 weeks to 3 months, the membranes and surrounding SC tissue were explanted; formalin-fixed; paraffin-embedded; and stained with hematoxylin and eosin (H&E) or Masson’s trichrome stain. The presence or absence of a fibrotic capsule was noted and its extent quantified histologically.
We observed that certain PTFE membranes (which we note were also used by the Pipeleers group) elicited varying degrees of FBR in athymic nude rats. The greatest response was seen with small-pore BioporeTM membranes; a vigorous FBR was evident as early as 3 weeks (Figure 1) and persisted to 3 months, a finding consonant with histology in immunocompetent Sprague-Dawley (SD) rats reported 30 years ago by Brauker et al. 10 These data1,10,11 substantiate that the nude rat mirrors the FBR seen in immunocompetent SD rats. Important to experimental design, three weeks is a valid histologic endpoint with which to identify a predisposition to FBR of a SC-implanted device. Further direct evidence has also been provided by Clayton et al. 12 , who observed that acellular alginate-poly-l-lysine capsules of various compositions elicited a FBR in nude rats.
Figure 1.

BioporeTM membrane and the surrounding SC tissue retrieved 3 weeks after implantation in a male Crl:NIH-Foxn1 rnu athymic nude rat. Shown, above, are H&E stained and, below, Masson’s trichrome stained FFPE sections. Note that the PTFE membrane elicited a strong FBR, resulting in the generation of multinucleated giant cells and a fibrotic capsule, measuring ~230 µm, surrounding the membrane. Similar but less severe FBR was seen with implantation of certain other PTFE membranes (10× objective; magnification = 100×).
Fibrosis is the principal host defense against implanted devices, whether or not they contain cells 10 . Consequently, strategies to abrogate the FBR and animal models to evaluate the success—or failure—of these approaches, are critical elements of preclinical development of implantable devices (reviewed in Papas et al. 13 and Anderson et al. 14 ). We echo the findings reported by the Pipeleers group lending strong support to the choice of the athymic nude rat model rather than the nude or SCID mouse to foretell whether an adverse foreign body response (FBR) will occur in humans to either cell-containing or acellular implanted devices.
Kelly M. Pasowisty
Department of Surgery, The University of Arizona, Tucson, AZ, USA
Amy C. Kelly
Department of Surgery, The University of Arizona, Tucson, AZ, USA
Trisha M. Fabijanic
Department of Surgery, The University of Arizona, Tucson, AZ, USA
Leah V. Steyn
Department of Surgery, The University of Arizona, Tucson, AZ, USA
Hannah A. Hagen
Department of Surgery, The University of Arizona, Tucson, AZ, USA
Thomas Loudovaris
Department of Surgery, The University of Arizona, Tucson, AZ, USA
Procyon Technologies LLC, Tucson, AZ, USA
Robert C. Johnson
Department of Surgery, The University of Arizona, Tucson, AZ, USA
Procyon Technologies LLC, Tucson, AZ, USA
Charles W. Putnam
Department of Surgery, The University of Arizona, Tucson, AZ, USA
Klearchos K. Papas
Department of Surgery, The University of Arizona, Tucson, AZ, USA
Procyon Technologies LLC, Tucson, AZ, USA
Acknowledgments
Not applicable.
Footnotes
ORCID iDs: Charles W. Putnam
https://orcid.org/0000-0002-4487-9358
Klearchos K. Papas
https://orcid.org/0000-0002-4554-0911
Research Ethics: All experiments were performed with the written approval of and in accordance with the guidelines established by the Institutional Animal Care and Use Committee at The University of Arizona, Approval number 12-392, August 8, 2024.
Patient Consent: Not applicable.
Author Contributions: Made a significant contribution to the concept, design, acquisition, analysis or interpretation of data: All authors. Drafted the article or revised it critically for important intellectual content: KMP,TL, RCJ, CWP, KKP. Approved the final version of the article for publication: KMP, CWP, KKP. Agreed to be accountable for all aspects of the work and resolved any issues related to its accuracy or integrity: All authors.
Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Breakthrough T1D (formerly JDRF) [3-SRA-2023-1437-M-B].
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: K.K.P. declares that he is an Associate Editor of Cell Transplantation. R.C.J., T.L, and K.K.P. declare that they are co-founders of and have financial interests in Procyon Technologies LLC. All other authors declare that they have no conflicts of interest.
Data Availability Statement: All relevant data are included in the manuscript.
Statement of Human and Animal Rights: This article does not contain any studies with human subjects. The use of animals is addressed in “Research Ethics” (above).
Statement of Informed Consent: There are no human subjects in this article and informed consent is not applicable.
References
- 1. Nijns JR, De Mesmaeker I, Suenens KG, Stangé GM, De Groot K, Marques de Lima M, Kraus MRC, Keymeulen B, Waelput W, Jacobs-Tulleneers Thevissen D, Pipeleers DG. Comparison of omentum and subcutis as implant sites for device-encapsulated human iPSC-derived pancreatic endoderm in nude rats. Cell Transplant. 2023;32:9636897231167323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Andersson A, Eizirik DL, Bremer C, Johnson RC, Pipeleers DG, Hellerström C. Structure and function of macroencapsulated human and rodent pancreatic islets transplanted into nude mice. Horm Metab Res. 1996;28(6):306–309. [DOI] [PubMed] [Google Scholar]
- 3. Robert T, De Mesmaeker I, Van Hulle FO, Suenens KG, Stangé GM, Ling Z, Haller C, Bouche N, Keymeulen B, Kraus MRC, Pipeleers DG. Cell mass increase associated with formation of glucose-controlling β-cell mass in device-encapsulated implants of hiPS-derived pancreatic endoderm. Stem Cells Transl Med. 2019;8(12):1296–1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Robert T, De Mesmaeker I, Stangé GM, Suenens KG, Ling Z, Kroon EJ, Pipeleers DG. Functional beta cell mass from device-encapsulated hESC-derived pancreatic endoderm achieving metabolic control. Stem Cell Reports. 2018;10(3):739–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Keymeulen B, De Groot K, Jacobs-Tulleneers-Thevissen D, Thompson DM, Bellin MD, Kroon EJ, Daniels M, Wang R, Jaiman M, Kieffer TJ, Foyt HL, et al. Encapsulated stem cell-derived β cells exert glucose control in patients with type 1 diabetes. Nat Biotechnol. 2024;42:1507–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Rolstad B. The athymic nude rat: an animal experimental model to reveal novel aspects of innate immune responses. Immunol Rev. 2001;184:136–44. [DOI] [PubMed] [Google Scholar]
- 7. Yang B, Rutkowski N, Elisseeff J. The foreign body response: emerging cell types and considerations for targeted therapeutics. Biomater Sci. 2023;11(24):7730–47. [DOI] [PubMed] [Google Scholar]
- 8. Rodriguez A, Macewan SR, Meyerson H, Kirk JT, Anderson JM. The foreign body reaction in T-cell-deficient mice. J Biomed Mater Res A. 2009;90(1):106–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Goodman S, Wang JS, Regula D, Aspenberg P. T-lymphocytes are not necessary for particulate polyethylene-induced macrophage recruitment. Histologic Studies of the Rat Tibia. Acta Orthop Scand. 1994;65(2):157–60. [DOI] [PubMed] [Google Scholar]
- 10. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC. Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Mater Res. 1995;29(12):1517–24. [DOI] [PubMed] [Google Scholar]
- 11. Steyn LV, Drew D, Vlachos D, Huey B, Cocchi K, Price ND, Johnson R, Putnam CW, Papas KK. Accelerated absorption of regular insulin administered via a vascularizing permeable microchamber implanted subcutaneously in diabetic Rattus norvegicus. PLoS ONE. 2023;18(6):e0278794. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Clayton HA, London NJ, Colloby PS, Bell PR, James RF. The effect of capsule composition on the biocompatibility of alginate-poly-l-lysine capsules. J Microencapsul. 1991;8(2):221–33. [DOI] [PubMed] [Google Scholar]
- 13. Papas KK, De Leon H, Suszynski TM, Johnson RC. Oxygenation strategies for encapsulated islet and beta cell transplants. Adv Drug Deliv Rev. 2019;139:139–56. [DOI] [PubMed] [Google Scholar]
- 14. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol. 2008;20(2):86–100. [DOI] [PMC free article] [PubMed] [Google Scholar]
